Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma (Q33430690)

26 July 2017

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma (English)

1 reference

26 July 2017

Sheridan M Hoy

1

1 reference

26 July 2017

14 March 2016

1 reference

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

2

1 reference

26 July 2017

255-262

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-016-0428-7

26 July 2017

0 references

cites work

Defining and treating high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Current treatment landscape for relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0428-7

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26972294

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-016-0428-7

1 reference

PubMed ID

26972294

Dimensions Publication ID

26 July 2017

0 references

1 reference

PubMed ID

26972294